接受异基因干细胞移植的急性髓系白血病患者降低复发风险的策略
本文综述了接受异基因干细胞移植的急性髓系白血病患者降低复发风险的策略,包括提高缓解率、降低移植前可测量残留病、增强移植物抗白血病效应及移植后维持治疗等方法,并指出未来进展依赖于创新性临床试验和协作网络的发展。
要点
- 异基因干细胞移植是成人急性髓系白血病的重要治愈手段,但复发仍是治疗失败的首要原因。
- 降低移植前可测量残留病和增强移植物抗白血病效应是减少复发的关键方向。
- 未来需通过创新性临床试验和协作网络快速评估新兴疗法。
核心结论
- 异基因干细胞移植是成人急性髓系白血病的重要治愈策略,但复发仍是治疗失败的首要原因,移植后复发患者预后仍差。
- 开发不增加移植毒性的新策略以减少疾病复发仍是优先事项。
- 未来进展依赖于创新性试验和协作网络的发展,以确保在前瞻性临床试验中快速评估新兴疗法。
研究设计与样本
- 综述,探讨基于疾病生物学和移植物抗白血病效应理解下的已确立、演进中和新颖的方法。
主要发现
- 讨论了提高缓解率、降低移植前可测量残留病、增强移植物抗白血病效应的未来方法以及移植后维持治疗的机会。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic stem cell transplantation is a centrally important curative strategy in adults with acute myeloid leukaemia; however, relapse occurs in a significant proportion of patients and remains the leading cause of treatment failure. The prognosis for patients who relapse post-transplant remains poor, and the development of new strategies with the ability to reduce disease recurrence without increasing transplant toxicity remains a priority. In this review, within the context of our understanding of disease biology and the graft-versus-leukaemia (GVL) effect, we will discuss established, evolving and novel approaches for increasing remission rates, decreasing measurable residual disease pretransplant, future methods to augment the GVL effect and the opportunities for post-transplant maintenance. Future progress depends upon the development of innovative trials and networks, which will ensure the rapid assessment of emerging therapies in prospective clinical trials.
引用
- Kinsella FAM, Maroto MAL, Loke J, et al. Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia. Br J Haematol. 2024. PMID: 38602216. doi:10.1111/bjh.19463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。